790 results on '"Koh, Kwang Kon"'
Search Results
2. Association of pericardial adipose tissue with left ventricular structure and function: a region‐specific effect?
3. Metabolic syndrome awareness in the general Korean population: results from a nationwide survey
4. Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease
5. Metabolic syndrome epidemic among Korean adults: Korean survey of Cardiometabolic Syndrome (2018)
6. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
7. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)
8. Comparison of metabolic and inflammatory markers in non-obstructive coronary artery disease patients according to metabolic syndrome
9. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk
10. Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients
11. Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia
12. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
13. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia
14. The role of insulin resistance and metabolic risk factors on culprit coronary plaque
15. Glycated Hemoglobin and Waist-to-Hip Circumference Ratio Reflect the Long-Term Status of Metabolic Conditions Are Independent Markers for Coronary Endothelial Dysfunction in Humans: The Prospective Registry With Cross-Sectional Analysis
16. PS-BPC02-5: IMPACT OF LONGITUDINAL CHANGES IN METABOLIC SYNDROME STATUS OVER TWO YEARS ON 10-YEAR INCIDENT TYPE 2 DIABETES MELLITUS
17. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia
18. Early repolarization is associated with atrial and ventricular tachyarrhythmias in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
19. How to balance cardiorenometabolic benefits and risks of statins
20. Modulation of adiponectin as a potential therapeutic strategy
21. Letter by Koh Regarding Article, “Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)”
22. Letter by Koh Regarding Article, “Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)”
23. Letter by Koh Regarding Article, “PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)”
24. Letter by Koh Regarding Article, “Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease”
25. Letter by Koh Regarding Article, “Low-Calorie Vegetarian Versus Mediterranean Diets for Reducing Body Weight and Improving Cardiovascular Risk Profile: CARDIVEG Study (Cardiovascular Prevention With Vegetarian Diet)”
26. Letter by Koh Regarding Article, “Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)”
27. Letter by Koh Regarding Article, “J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets: An Experimental Approach to an Observational Paradigm”
28. Letter by Koh Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”
29. Perivascular adipose tissue in the pathogenesis of cardiovascular disease
30. Comparative cardiometabolic effects of fibrates and omega-3 fatty acids
31. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality
32. Diffuse multi-vessel coronary artery spasm: Incidence and clinical prognosis
33. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
34. How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol
35. Letter by Koh Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”
36. Letter by Koh Regarding Article, “Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)”
37. Letter by Koh Regarding Article, “Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells”
38. Letter by Koh Regarding Article, “Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey)”
39. Letter by Koh Regarding Article, “Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?”
40. Letter by Koh Regarding Articles, “Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)” and “Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population”
41. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia
42. Differential metabolic effects of distinct statins
43. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension
44. Letter by Koh Regarding Article, “Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial”
45. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs
46. Combination therapy for treatment or prevention of atherosclerosis: Focus on the lipid-RAAS interaction
47. Amlodipine improves endothelial function and metabolic parameters in patients with hypertension
48. Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies
49. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients
50. Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.